The EPS beat and strong cash runway are positive, but the stock's move will hinge on APEX Phase 2 Part B data expected in Q2 2026. Monitor for the Part B readout and any updates on asthma/EoE trial designs later this year. The $403M offering was already priced in post-March 2026 readout; near-term focus is on execution toward Phase 3.
APGE drugs
APGE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $84.60entry
- T+1 · 6mo ago −1.97%α −1.84% · $82.93
- T+5 · 6mo ago −6.91%α −6.83% · $78.75
- T+20 · 5mo ago +0.47%α +0.78% · $85.00
- T+60 · 3mo ago +58.66%α +54.27% · $134.23
Price Chart
How similar events traded
Executive Summary
Apogee Therapeutics reported Q1 2026 EPS of -$1.03, a 9% beat vs consensus of -$1.13, with no revenue. The company highlighted durable 52-week Phase 2 data for zumilokibart in atopic dermatitis and a $403M upsized equity offering extending cash runway into 2029. Net loss widened to $74.1M from $55.3M YoY on higher R&D and G&A spend, but the pipeline catalyst (Phase 2 Part B data in Q2 2026 and Phase 3 initiation in 2H 2026) overshadows the loss expansion.
Key Financial Metrics
Key Facts
- EPS of -$1.03 beat consensus of -$1.13 by 9%
- No revenue (pre-commercial biotech)
- Cash position $1.3B as of March 31, 2026, up from $902.9M at Dec 31, 2025, following $403M upsized equity offering
- Net loss widened to $74.1M from $55.3M YoY on higher R&D ($60.8M vs $46.4M) and G&A ($22.0M vs $16.7M) expenses
- APEX Phase 2 Part A 52-week data showed durable maintenance with 3- and 6-month dosing; 75-85% of Week 16 EASI-75 responders maintained at Week 52
- APEX Phase 2 Part B 16-week data expected in Q2 2026; Phase 3 initiation in AD expected in 2H 2026
- Positive Phase 1b asthma data reported January 2026; expansion into asthma and EoE trials planned later this year
- Cash runway into 2029 supports BLA filing for zumilokibart in AD
Financial Impact
EPS beat of 9% on consensus -$1.13; cash position strengthened to $1.3B from $902.9M
Risk Factors
- Clinical trial failure risk, Part B data may not replicate Part A durability
- Dilution from $403M equity offering already completed; no further near-term dilution expected
- Widening net loss trajectory with no near-term revenue; reliance on capital markets for future funding
- Competitive landscape in AD (DUPIXENT, lebrikizumab, others)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291754 |
Track record
31 reports on APGE
8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.
Filters
- Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
- Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
- Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
- Aug 10, 202614w ago 8-K Bullish 8/10 No price data
- Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
- Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
- Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
- Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers